ABSTRACT
@EN We studied the effect of rhGH on the growth in seven children with chronic renal failure (CRF). All seven children showed normal GH responses (peak GH response, more than 10ng/mL) to classical GH provocative tests (L-dopa, Arginine), which
results
did not differ from that of healthy children.
The change of height SDS for 1 year of rhGH treatment was from -3.47±1.31 to -2.74±1.57, which had no statistical significance (p>0.1) (Fig. 1, Table 2).
The growth velocity during 1 year prior to and following rhGH treatment increased from 2.78±0.85cm/year to 11.24±7.90cm/year, respectively, which had statistical significance (p<0.05) (Fig. 2, Table 2). One child who had had successful renal
transplantation showed an increase in the height SDS from -5.4 ot -4.0 and an increase in the growth velocity from 3.2cm/year to 12.2cm/year with rhGH treatment.
The predicted adult height, obtained by Tanner-Whitehouse method, following GH treatment increased from 151.9±5.7cm to 160.4±10.3cm, which had marginally statistical significance (p=0.05) (Fig. 3, Table 2).
Subcutaneous fat mass measured with triceps subcutaneous skin fold, decreased significantly with significant increase in muscle mass following rhGH treatment (p<0.05) (Fig. 4).
Through the period of rhGH treatment, we could not observe any side effect of GH treatment, such as hypothyroidism, glucose intolerance, or aggravation of renal function. Also we could not observe any exaggerated advancement of bone maturation
(0.6±0.2
year/chronological year) during rhGH treatment, but less than the advancement of chronological age. (J Kor Endocrinol 8:157~163, 1993)
|